Want to see JP:4534 full AI Analyst Report?
4534 Stock Chart & Stats
¥3615.00
-¥40.00(-1.17%)
At close: 4:00 PM EST
¥3615.00
-¥40.00(-1.17%)
Day’s Range― - ―
52-Week Range¥2,929.00 - ¥3,965.00
Previous CloseN/A
Volume18.00K
Average Volume (3M)34.37K
Market Cap
¥106.17B
Enterprise Value¥95.36K
Total Cash (Recent Filing)¥31.06B
Total Debt (Recent Filing)¥10.00B
Price to Earnings (P/E)14.0
Beta0.65
Next Earnings
Oct 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.56%
Share Statistics
EPS (TTM)222.94
Shares Outstanding36,390,000
10 Day Avg. Volume38,620
30 Day Avg. Volume34,366
Financial Highlights & Ratios
PEG Ratio0.40
Price to Book (P/B)0.87
Price to Sales (P/S)1.05
P/FCF Ratio-12.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)208.3
Revenue Forecast (FY)¥110.00B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetMochida's historically near-zero leverage and large equity base provide durable financial flexibility, allowing continued R&D and product commercialization during downturns. Low structural leverage reduces bankruptcy risk and supports strategic optionality over the next several quarters.
Rebounding Revenue And ProfitabilitySustained revenue growth and rising net income through 2026 indicate improving product performance and sales execution. Over 2–6 months this trend supports reinvestment capacity, strengthens operating leverage potential, and suggests the core business has regained momentum after prior weakness.
Specialized Therapeutic Focus And Domestic Sales NetworkA focused product mix in dermatology and gynecology plus a dedicated domestic salesforce creates durable competitive advantages: specialized sales relationships, regulatory know-how, and predictable hospital/clinic channels that support steady demand and defend margins over time.
Bears Say
Volatile Cash GenerationIrregular OCF and FCF undermine the company's ability to self-fund R&D, sustain dividends, or respond to opportunities. Persistent swings tied to working-capital variability reduce predictability of capital allocation and increase reliance on external financing over the medium term.
Margin And Earnings InconsistencyVolatile margins mean profitability may be sensitive to product mix, pricing or cost pressures. This weakens confidence in sustainable margin expansion and complicates forecasting, making long-term investment and capacity decisions riskier despite recent profit rebounds.
Rising Debt Level In 2026The 2026 debt increase, while modest relative to equity, reduces the previous low-leverage cushion. Combined with weak cash conversion, higher debt could constrain strategic flexibility and raise refinancing or interest risks over the medium term if cash generation does not stabilize.
Mochida Pharmaceutical Co., Ltd. News
4534 FAQ
What was Mochida Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Mochida Pharmaceutical Co., Ltd. lowest stock price was ¥2929.00 and its highest was ¥3965.00 in the past 12 months.
What is Mochida Pharmaceutical Co., Ltd.’s market cap?
Mochida Pharmaceutical Co., Ltd.’s market cap is ¥106.17B.
When is Mochida Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Mochida Pharmaceutical Co., Ltd.’s upcoming earnings report date is Oct 30, 2026 which is in 84 days.
How were Mochida Pharmaceutical Co., Ltd.’s earnings last quarter?
Mochida Pharmaceutical Co., Ltd. released its earnings results on Aug 03, 2026. The company reported ¥89.77 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Mochida Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Mochida Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Mochida Pharmaceutical Co., Ltd. pay dividends?
Mochida Pharmaceutical Co., Ltd. pays a Semiannually dividend of ¥42.5 which represents an annual dividend yield of 2.56%. See more information on Mochida Pharmaceutical Co., Ltd. dividends here
What is Mochida Pharmaceutical Co., Ltd.’s EPS estimate?
Mochida Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mochida Pharmaceutical Co., Ltd. have?
Mochida Pharmaceutical Co., Ltd. has 36,390,000 shares outstanding.
What happened to Mochida Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Mochida Pharmaceutical Co., Ltd. reported an EPS of ¥89.77 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.923%.
Which hedge fund is a major shareholder of Mochida Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4534
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mochida Pharmaceutical Co., Ltd.
Established in 1913 and headquartered in Tokyo, Japan, Mochida Pharmaceutical Co., Ltd. specializes in the development, manufacturing, and distribution of a wide array of medical and personal care products. Its primary offerings encompass pharmaceuticals, diagnostic solutions, and skincare lines. The company's extensive pharmaceutical portfolio includes treatments for a variety of conditions, such as cardiovascular issues, pain (analgesics), gastrointestinal ailments, neurological disorders, infections (anti-infectives), diabetes (antidiabetics), and cancer (oncological agents). Additionally, it provides hormone and biological preparations, alongside biosimilars, catering to therapeutic areas like dermatology, psychiatry, obstetrics, and gynecology. In diagnostics, Mochida produces various reagents, particularly those utilized for fertility and infertility assessments. Its skincare division features products designed for facial, body, and hair care. Beyond its existing product range, Mochida Pharmaceutical actively invests in research and development, with a specific focus on creating therapies for intractable diseases. The company has also forged strategic collaborations, including a partnership with Amarin Corporation plc for the advancement and market introduction of ethyl icosapentate products. Furthermore, it collaborates with Gene Techno Science Co., Ltd. to innovate regenerative medicine targeting rare and challenging digestive disorders, such as congenital isolated hypoganglionosis.
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Towa Pharmaceutical Co
―
KYORIN Pharmaceutical Co.,Ltd.
―
SAWAI GROUP HOLDINGS Co., Ltd.
―